Islet β-Cells Deficient in Bcl-xL Develop but Are Abnormally Sensitive to Apoptotic Stimuli
Emma M. Carrington(The University of Melbourne), Janette Allison(The Royal Melbourne Hospital), Andreas Strasser(The University of Melbourne), Michelle Myers(Nucana (United Kingdom)), Elisa S. Jansen(Walter and Eliza Hall Institute of Medical Research), Cameron Kos(St Vincents Institute of Medical Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Stacey Fynch(St Vincents Institute of Medical Research), Mark McKenzie, Thomas W. H. Kay(The University of Melbourne)
Cited by 47
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis.
|The EMBO Journal|1995|788
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
|The Journal of Experimental Medicine|2012|670